Therapeutic Solutions International Inc (TSOI)

[centsability4me]

TSOI DD/News/SS

Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases

http://therapeuticsolutionsint.com/

Biologics, Pharmaceutical, Nutraceuticals

Bio Arena

On the Right To Try Pathway for Treatment, Prevention, or Treatment and Prevention of :

Stage 1 - 4 Cancers (Tumor types), w/ StemVacs Dendritic Cell Vaccine / Immunotherapy Platform, and NanoStilbeneTM
CTE - Chronic Traumatic Encephalopathy w/ Mesenchymal Stem Cells, Autologous Neurogenic Stem Cell Banking, and NeuroStilbene
TBI - Traumatic Brain Injury w/ Mesenchymal Stem Cells, and NeuroStilbene
CRS - Cytokine Release Syndrome / Inflammation w/ NanoStilbeneTM

Right to Try Background Info :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146010503

Products

6 Biologics

StemVacs
MemoryMune
innaMune
BRS-001
sRNA augmented stem cell
jadi cell

1 Pharmaceutical
LymphoBoost

7 Nutraceuticals
Projuvenol
NanoStilbene
DermalStilbene
IsoStilbene
NeuroStilbene
Alpha Lipoic Acid
Cancer Metabolic De Tox

4 TSOI nutraceutical products for sale online
Projuvenol, Nanostilbene, DermalStilbene, NeuroStilbene
E-commerce site
http://www.youcanordernow.com/



TSOI Patent Search
https://patents.google.com/?assignee=Therapeutic+Solutions+International+Inc

TSOI Patent Portfolio
https://therapeuticsolutionsint.com/?page_id=68

TSOI Scientific Advisory Board Members
https://therapeuticsolutionsint.com/?page_id=64

TSOI NEWS HISTORY 5/1/18- 12/31/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145938143

TSOI Most Recent NEWS

NEWS 1/14/19
https://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79045322/therapeutic-solutions-international-announces-prel

Therapeutic Solutions International Announces Preliminary Data for Immune Stimulation in Advanced Cancer Patients by Commercially Available Product

NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients
through Modulation of Inflammatory Mediators

OCEANSIDE, CA -- January 14, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today early results of a clinical trial suggesting efficacy of its product NanoStilbene in increased activity of immune system cells termed "Natural Killer" cells in advanced cancer patients, as well as enhancing production of interferon gamma, a protein associated with suppression of cancer growth.

The study assessed whether the administration of NanoStilbene, a nanoformulation of pterostilbene, is effective at reducing inflammatory markers and augmenting immune function in 12 advanced cancer patients.

It has previously been known that pterostilbene possesses direct anticancer activity in the majority of cancers including melanoma1, glioma2, ovarian cancer3, prostate cancer4, pancreatic cancer5, breast cancer6, liver cancer7, colorectal cancer8, and various liquid tumors (leukemias)9.

"Chronic inflammation, as measured by CRP, TNF-alpha and IL-6 levels in the blood, has been reported to be immune suppressive in cancer patients10 and we sought to reduce them through orally administered NanoStilbene," said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. "On average we saw CRP reduced by 27%, Interleukin 6 (IL-6) by 26% and TNF-alpha also by 26%. This dramatic reduction showed clinically relevant levels of downregulation of inflammatory cytokines as a result of the NanoStilbene administration."

"The suppression of interferon gamma (IFN-g) is a hallmark of cancer immune evasion. Given that this cancer immune evasion is typically associated with inflammatory mediators such as TNF-alpha, we assessed the impact of NanoStilbene administration on the production of interferon gamma. We observed an average increase by 12% among the patients treated" said Dr. Thomas Ichim, Director of Therapeutic Solutions International. "The augmentation of interferon gamma production was due to the reduction of pro-inflammatory cytokines CRP, TNF-a, and IL-6, and we feel strongly that patients should be on a 300mg dose of NanoStilbene daily for the duration of their treatment, added Dr. Ichim."

"The augmentation of natural killer cell (NK) activity is one of the most sensitive indicators of anticancer immunity we see clinically. Previous studies have shown that efficacy of antibody, as well as chemotherapy-induced cancer cell death, is dependent on NK activity. Unfortunately, cancer patients have suppressed NK activity, usually as a result of oxidative stress, therefore, it was postulated that NanoStilbene may reverse cancer associated NK depression" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "We observed on average an increase in NK activity of 37% in these very sick patients, validating that 300mg of nanoparticle pterostilbene (1.5 milliliters) daily was sufficient to cause such dramatic results not usually seen even with FDA approved drugs."

Results here :
https://nanostilbene.com/?page_id=301

NEWS 1/9/19

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
Patent filed for Autologous Neurogenic Cells in Professional Athletes at Risk of CTE
http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79022244/therapeutic-solutions-international-continues-to-e

OCEANSIDE, CA -- January 09, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the addition and expansion to their CTE portfolio of intellectual property with the filing of a new patent application.

The invention pertains to the field of cellular therapies, more particularly, the invention pertains to the use of banking of autologous cells, and the manipulation of autologous cells for treatment of CTE.

CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.

"This new means of obtaining autologous cells and banking them for use in the treatment and prevention of CTE is a new and novel approach. The autologous regenerative cells are banked for future administration in the same patient when the patient begins to develop signs of CTE or possesses an upregulation of markers associated with the probability of CTE onset" said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc.

"Banking of autologous cells is a well-known procedure which has generated considerable revenue despite little practical value. For example, the only FDA approved means of utilizing cord blood cells is for treatment of pediatric leukemias, however, in these situations, allogeneic cells are required due to the possibility of autologous cells possessing proclivity towards leukemic transformation. The current patent provides tissue banking means for athletes at risk of CTE and means of utilizing the autologous cells" said Dr. Thomas Ichim, Board Member of Therapeutic Solutions International. "The possibility of using regenerative cells such as stem cells is limited by a lack of autologous cell sources. Our invention provides means of banking and utilizing autologous cells for use in patients with CTE."

Share Structure
https://www.otcmarkets.com/stock/TSOI/security
AS - 2.5 B common , 5 M preferred - https://www.nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=LvtIoYTPV6wB1RIovm008A%253d%253d&nt7=0
IO - 1,011,063,182
Restricted - 854,729,214
Unrestricted - 156,333,968
Held at DTC - 133,690,968
Float - 105,109,529
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=therapeutic+solutions+international&match=contains&action=getcompany

Transfer Agent
New Horizon Transfer Inc.
215-515 West Pender Street
Vancouver, BC V6B 6H5
CAN(604) 876-5526
www.newhorizontransfer.com

TSOI Management / Board of Directors
https://therapeuticsolutionsint.com/?page_id=62

Contact

Investor Relations
[e-mail]
Corporate Website
http://therapeuticsolutionsint.com/
Additional info
http://projuvenol.com/
https://nanostilbene.com/
http://stemvacs.com/
TSOI on Facebook
https://www.facebook.com/tsoihome/
TSOI on Twitter
https://twitter.com/tsoisupplement